Matrix metalloproteinase therapy in heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 4, 2009, Pages 339-346

  Spinale, Francis G ^a   Wilbur, Nikole M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PG 116800; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HUMAN; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR;

EID: 67651113672     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0034-4     Document Type: Review

References (37)

1. Spinale FG: Matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
2. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: Critical steps toward clinical applications. Am J Physiol 2004, 286:H1-H10.
3. Spinale FG, Coker ML, Heung LJ, et al.: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
4. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF: Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: Role of metalloproteinases and pyridinoline cross links. Am J Pathol 1996, 148:1639-1648.
5. Spinale FG, Krombach RS, Coker ML, et al.: Matrix metalloproteinase inhibition during developing congestive heart failure in pigs: Effects on left ventricular geometry and function. Circ Res 1999, 85;364-376.
6. Creemers E, Davis JN, Parkhurst AM, et al.: Deficiency of the tissue inhibitor of matrix metalloproteinase-1 gene exacerbates LV remodeling following myocardial infarction in mice. Am J Physiol 2003, 284:H364-H371.
7. Heymans S, Luttun A, Nuyens D, et al.: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999, 5:1135-1142.
8. Ducharme A, Frantz S, Aikawa M, et al.: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55-62.
9. Li YY, Feng Y, McTiernan CF, et al.: Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104: 1147-1152.
10. Su H, Spinale FG, Dobrucki LW, et al.: Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005, 112:3157-3167.
11. Doughty RN, Whalley GA, Gamble G, et al.: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997, 29:1060-1066.
12. St. John Sutton M, Pfeffer MA, Plappert T, et al., for the SAVE Investigators: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after myocardial infarction. The protective effects of captopril. Circulation 1994, 89:68-75.
13. Li YY, Feldman AM, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98:1728-1734.
14. Greene J, Wang M, Liu YE, et al.: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996, 271:30375-30380.
15. Liu YE, Wang M, Greene J, et al.: Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997, 272:20479-20483.
16. Matsumura S, Iwanaga S, Mochizuki S, et al.: Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005, 115:599-609.
17. Mukherjee R, Brinsa TA, Dowdy KB, et al.: Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003, 107:618-625.
18. Yarbrough WM, Mukherjee R, Escobar GP, et al.: Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003, 108:1753-1759.
19. Tian H, Cimini M, Fedak PW, et al.: TIMP deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 2007, 43:733-743.
20. Kai H, Ikeda H, Yusakawa H, et al.: Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
21. Hojo Y, Ikeda U, Ueno S, et al.: Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001, 65:71-75.
22. Webb CS, Bonnema DD, Ahmed SH, et al.: Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 2006, 114:1020-1027.
23. Orn S, Manhenke C, Squire IB, et al.: Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail 2007, 13:843-849.
24. Fukuda D, Shimada K, Tanaka A, et al.: Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006, 97:175-180.
25. Squire IB, Evans J, Ng LL, et al.: Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004, 10:328-333.
26. Hlatky MA, Ashley E, Quertermous T, et al.: Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study: Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J. 2007, 154: 1043-1051.
27. Manginas A, Bei E, Chaidaroglou A, et al.: Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponin I. Clin Cardiol 2005, 28:182-186.
28. Kelly D, Khan S, Cockerill G, et al.: Circulating stromelysin-1(MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008, 10:133-139.
29. Sabatine MS, Ploughman L, Simonsen KL, et al.: Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol 2008, 28:562-567.
30. Gurbel PA, Kreutz RP, Bliden KP, et al.: Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression. Am Heart J 2008, 155:56-61.
31. Orn S, Manhenke C, Squire IB, et al.: Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail 2007, 13:843-849.
32. Elmas E, Lang S, Dempfle CE, et al.: High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8(IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med 2007, 45:1360-1365.
33. Schmidt R, Bültmann A, Fischel S, et al.: Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008, 102:302-309.
34. Schmidt R, Bültmann A, Ungerer M, et al.: Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: Implications in acute myocardial infarction. Circulation 2006, 113:834-841.
35. Jung K: A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure. J Intern Med 2008, 264:291-293.
36. Hudson MP, Armstrong PW, Ruzyllo W, et al.: Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006, 48:15-20.
37. Deschamps AM, Yarbrough WM, Squires CE, et al.: Trafficking of the membrane type-1 matrix metalloproteinase (MT1-MMP) in ischemia and reperfusion: Relation to interstitial MT1-MMP activity. Circulation 2005, 111:1166-1174.